PMID- 18671786
OWN - NLM
STAT- MEDLINE
DCOM- 20081231
LR  - 20191210
IS  - 1464-410X (Electronic)
IS  - 1464-4096 (Linking)
VI  - 102
IP  - 9
DP  - 2008 Nov
TI  - Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer.
PG  - 1092-6
LID - 10.1111/j.1464-410X.2008.07897.x [doi]
AB  - OBJECTIVE: To evaluate the subclassifications of pT2 diseases in 
      tumour-nodes-metastases (TNM) staging system for prostate cancer. PATIENTS AND 
      METHODS: We retrospectively analysed the data of 372 patients who underwent 
      radical retropubic prostatectomy (RRP) for pathologically organ-confined prostate 
      cancer at our institution. Pathological staging of all subjects were re-evaluated 
      using the 1997 and the 2002 TNM staging system for prostate cancer. Various 
      clinicopathological features along with biochemical recurrence-free survival 
      (BRFS) of pT2 subgroups were assessed. RESULTS: Using the 2002 TNM staging 
      criteria, 87 of the tumours (23.4%) were pT2a, and 284 (76.3%) were pT2c. Of all 
      subjects, there was only one (0.3%) pathological 2002 T2b tumour identified. When 
      subjects were classified according to the 1997 versions of the T2 
      subclassification (pT2a vs pT2b), the 1997 pT2a and pT2b cases showed no 
      significant difference regarding BRFS (log-rank P = 0.645) among those who were 
      followed-up for >2 years after RRP. Also, pathological stage (1997 pT2a vs pT2b) 
      was not a significant predictor of BRFS in either uni- or multivariate analysis 
      (P = 0.289 and P = 0.241, respectively). Only preoperative serum PSA level and 
      pathological Gleason score along with positive surgical margin were significant 
      predictors of PSA outcome after RRP on multivariate analysis. CONCLUSION: Our 
      results suggest that two- or three-tiered subclassification of pT2 organ-confined 
      prostate cancer via methods used in the previous or current TNM staging system 
      may not be appropriate. Efforts should be made to upgrade the current TNM staging 
      system for prostate cancer.
FAU - Hong, Sung Kyu
AU  - Hong SK
AD  - Department of Urology, Seoul National University Bundang Hospital, Seongnam, 
      Korea.
FAU - Han, Byung Kyu
AU  - Han BK
FAU - Chung, Jae Seung
AU  - Chung JS
FAU - Park, Dong-Soo
AU  - Park DS
FAU - Jeong, Seong Jin
AU  - Jeong SJ
FAU - Byun, Seok-Soo
AU  - Byun SS
FAU - Choe, Gheeyoung
AU  - Choe G
FAU - Lee, Sang Eun
AU  - Lee SE
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20080729
PL  - England
TA  - BJU Int
JT  - BJU international
JID - 100886721
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Disease-Free Survival
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local/pathology
MH  - Neoplasm Staging/*standards
MH  - Prostate/*pathology/surgery
MH  - Prostate-Specific Antigen/blood
MH  - Prostatectomy/*methods
MH  - Prostatic Neoplasms/*pathology/surgery
MH  - Retrospective Studies
EDAT- 2008/08/02 09:00
MHDA- 2009/01/01 09:00
CRDT- 2008/08/02 09:00
PHST- 2008/08/02 09:00 [pubmed]
PHST- 2009/01/01 09:00 [medline]
PHST- 2008/08/02 09:00 [entrez]
AID - BJU7897 [pii]
AID - 10.1111/j.1464-410X.2008.07897.x [doi]
PST - ppublish
SO  - BJU Int. 2008 Nov;102(9):1092-6. doi: 10.1111/j.1464-410X.2008.07897.x. Epub 2008 
      Jul 29.